



Index

1	Introduction	1
1.1	Drug transit through the upper GI tract.....	2
1.2	Determinants of drug absorption	4
1.2.1	The biopharmaceutics classification system	4
1.2.2	The biopharmaceutics drug disposition classification system.....	5
1.2.3	The developability classification system	6
1.3	Weak bases and the GI tract.....	7
1.3.1	pH in the GI tract	7
1.3.2	Bile salts and food in the GI tract	9
1.3.3	Gastric emptying	10
1.4	Simulation of <i>in vivo</i> drug dissolution	10
1.4.1	Dissolution media simulating GI fluids	10
1.4.2	Simulation of GI dissolution conditions	11
1.5	Drug permeability assessment	14
1.6	Physiologically based pharmacokinetic modeling	16
1.6.1	PBPK modeling approaches	16
1.6.2	Software for PBPK modeling.....	17
1.6.2.1	<i>MATLAB[®] and STELLA[®]</i>	17
1.6.2.2	<i>Commercial software (Simcyp[®], GastroPlus[®], PK-Sim[®]) and GI-Sim[®]</i>	18
1.7	Aims of this work	20
2	Materials and Methods.....	21
2.1	Materials.....	21
2.1.1	Chemicals	21
2.1.2	Model substance cinnarizine.....	22
2.1.3	Model substance atazanavir	24
2.2	Methods.....	28
2.2.1	HPLC-UV setup.....	28
2.2.2	Biorelevant media	29
2.2.3	Solubility assessment.....	31
2.2.4	Dissolution experiments	33
2.2.5	“Dumping” experiments.....	33
2.2.6	Transfer experiments	33
2.2.7	WinNonLin [®] - assessment of pharmacokinetics of API formulations	38
2.2.8	STELLA [®]	39
2.2.9	Simcyp [®]	47
2.2.10	Statistical comparison of predicted plasma profiles using different transfer experiment approaches	51



3	Results	52
3.1	Cinnarizine – investigation of <i>in vitro</i> behavior	52
3.1.1	Solubility results	52
3.1.2	Dissolution of cinnarizine tablets in biorelevant media	53
3.1.3	Dumping of pure cinnarizine	57
3.1.4	Investigation of supersaturation and precipitation of cinnarizine during transfer experiments	58
3.2	Cinnarizine - <i>in silico</i> plasma profile simulation	66
3.2.1	Evaluation of distribution and elimination kinetics of various cinnarizine tablets using WinNonLin®	66
3.2.2	STELLA® model - investigation of permeability restrictions of cinnarizine using fed state simulations	67
3.2.3	STELLA® “dissolution-only” vs. “supersaturation and precipitation” PBPK model in cinnarizine fasted state simulations	69
3.2.4	STELLA® statistical comparison analysis of different transfer rates	73
3.2.5	STELLA® sensitivity analysis of cinnarizine plasma profile predictions	74
3.2.6	Summary of cinnarizine plasma profile simulations using Simcyp®	77
3.3	Summary of the cinnarizine investigation and formulation suggestions	78
3.4	Atazanavir sulfate – investigation of <i>in vitro</i> behavior	80
3.4.1	Solubility results	80
3.4.1.1	<i>Equilibrium solubility</i>	80
3.4.1.2	<i>Kinetic solubility</i>	82
3.4.2	Dissolution results of atazanavir sulfate capsules in biorelevant media	83
3.4.3	Dumping results of atazanavir sulfate	87
3.4.4	Investigation of the atazanavir sulfate concentration profile during simulated transfer from the stomach to the intestine	88
3.5	Atazanavir sulfate - <i>in silico</i> plasma profile simulation	95
3.5.1	Evaluation of distribution and elimination kinetics of atazanavir using WinNonLin® analysis of literature PK data	95
3.5.2	Permeability evaluation of atazanavir	96
3.5.3	STELLA® plasma profile predictions of atazanavir capsules in the fasted state	97
3.5.4	STELLA® sensitivity analysis on atazanavir plasma profile predictions	104
3.6	Summary of atazanavir plasma profile simulations using Simcyp®	109
3.7	Summary of the atazanavir investigation and formulation suggestions	110
4	General discussion and conclusions	113
4.1	Choosing the right <i>in vitro</i> investigation approach	113
4.2	Formulation enhancement approaches for weakly basic drugs	120
4.3	Choosing the right PBPK modeling approach	122
4.3.1	Development and evolution of the STELLA® model	122



4.3.2	Self-built versus commercial PBPK models (STELLA [®] versus Simcyp [®])	123
4.3.2.1	<i>Input of release and dissolution profiles</i>	124
4.3.2.2	<i>Opportunities for simulating pharmacokinetics of modified release formulations</i>	125
4.3.2.3	<i>Input of permeability</i>	125
4.3.2.4	<i>Middle-out and Bottom-up modeling approaches</i>	126
4.3.2.5	<i>Virtual populations</i>	127
4.3.2.6	<i>Summary</i>	127
4.4	Outlook	128
5	Summary	131
6	German Summary (Deutsche Zusammenfassung)	137
7	Appendix	143
7.1	STELLA [®] sensitivity analysis of cinnarizine plasma profile predictions.....	143
7.2	STELLA [®] sensitivity analysis of atazanavir sulfate plasma profile predictions.....	145
7.3	Simcyp [®] plasma profile predictions of cinnarizine	148
7.3.1	Simcyp [®] plasma profile predictions of cinnarizine in the fasted state	148
7.3.2	Simcyp [®] plasma profile predictions of cinnarizine in the fed state	155
7.3.3	Simcyp [®] sensitivity analysis of cinnarizine plasma profile predictions	161
7.3.4	Simcyp [®] plasma profile predictions of cinnarizine using fitted Vd.....	172
7.4	Simcyp [®] plasma profile predictions of atazanavir	176
7.4.1	Simcyp [®] plasma profile predictions of atazanavir in the fasted state.....	176
7.4.2	Simcyp [®] plasma profile predictions of atazanavir in the fed state.....	184
7.4.3	Simcyp [®] sensitivity analysis of atazanavir plasma profile predictions.....	188
8	References	203
9	Curriculum Vitae	216
9.1	Personal Information	216
9.2	Professional experience	216
9.3	Education	217
10	Scientific Publications	218
10.1	Papers	218
10.2	Posters	218
11	Academic Teachers	218